Logo image of FIXX

HOMOLOGY MEDICINES INC (FIXX) Stock Fundamental Analysis

NASDAQ:FIXX - Nasdaq - US4380831077 - Common Stock - Currency: USD

0.9347  +0.01 (+0.77%)

After market: 0.892 -0.04 (-4.57%)

Fundamental Rating

2

FIXX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. FIXX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FIXX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FIXX had negative earnings in the past year.
In the past year FIXX has reported a negative cash flow from operations.
In the past 5 years FIXX always reported negative net income.
In the past 5 years FIXX always reported negative operating cash flow.
FIXX Yearly Net Income VS EBIT VS OCF VS FCFFIXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

FIXX has a Return On Assets of -133.57%. This is amonst the worse of the industry: FIXX underperforms 85.71% of its industry peers.
With a Return On Equity value of -154.74%, FIXX is not doing good in the industry: 67.69% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROIC N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
FIXX Yearly ROA, ROE, ROICFIXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

FIXX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FIXX Yearly Profit, Operating, Gross MarginsFIXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

FIXX does not have a ROIC to compare to the WACC, probably because it is not profitable.
FIXX has more shares outstanding than it did 1 year ago.
FIXX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FIXX Yearly Shares OutstandingFIXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
FIXX Yearly Total Debt VS Total AssetsFIXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

FIXX has an Altman-Z score of -8.72. This is a bad value and indicates that FIXX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.72, FIXX is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
There is no outstanding debt for FIXX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.72
ROIC/WACCN/A
WACC9.71%
FIXX Yearly LT Debt VS Equity VS FCFFIXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 7.25 indicates that FIXX has no problem at all paying its short term obligations.
The Current ratio of FIXX (7.25) is better than 69.56% of its industry peers.
FIXX has a Quick Ratio of 7.25. This indicates that FIXX is financially healthy and has no problem in meeting its short term obligations.
FIXX has a Quick ratio of 7.25. This is in the better half of the industry: FIXX outperforms 69.56% of its industry peers.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 7.25
FIXX Yearly Current Assets VS Current LiabilitesFIXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

FIXX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.16%.
The Revenue for FIXX has decreased by -64.06% in the past year. This is quite bad
The Revenue for FIXX have been decreasing by -26.31% on average. This is quite bad
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, FIXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.92% on average per year.
Based on estimates for the next years, FIXX will show a quite strong growth in Revenue. The Revenue will grow by 10.76% on average per year.
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FIXX Yearly Revenue VS EstimatesFIXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
FIXX Yearly EPS VS EstimatesFIXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FIXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FIXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FIXX Price Earnings VS Forward Price EarningsFIXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FIXX Per share dataFIXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.87%
EPS Next 3Y9.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FIXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOMOLOGY MEDICINES INC

NASDAQ:FIXX (3/25/2024, 8:23:28 PM)

After market: 0.892 -0.04 (-4.57%)

0.9347

+0.01 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2024-03-13/bmo
Earnings (Next)05-09 2024-05-09/amc
Inst Owners0.11%
Inst Owner Change0%
Ins Owners15.02%
Ins Owner Change0%
Market Cap54.23M
Analysts43.33
Price Target1.53 (63.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.28%
Min EPS beat(2)-33.05%
Max EPS beat(2)8.5%
EPS beat(4)2
Avg EPS beat(4)-10.74%
Min EPS beat(4)-33.05%
Max EPS beat(4)8.5%
EPS beat(8)4
Avg EPS beat(8)-3.52%
EPS beat(12)8
Avg EPS beat(12)7.79%
EPS beat(16)10
Avg EPS beat(16)7.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.16
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.66
OCFYN/A
SpS0.02
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -133.57%
ROE -154.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.34%
ROA(5y)-52.65%
ROE(3y)-71.33%
ROE(5y)-63.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.45%
Cap/Sales 19.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 7.25
Altman-Z -8.72
F-Score2
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)56.06%
Cap/Depr(5y)112.08%
Cap/Sales(3y)22.33%
Cap/Sales(5y)302.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y64.09%
EPS Next 2Y27.87%
EPS Next 3Y9.98%
EPS Next 5Y12.92%
Revenue 1Y (TTM)-64.06%
Revenue growth 3Y-24.63%
Revenue growth 5Y-26.31%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y29.1%
Revenue Next 3Y18.56%
Revenue Next 5Y10.76%
EBIT growth 1Y30.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.61%
EBIT Next 3Y32.15%
EBIT Next 5Y37.25%
FCF growth 1Y16.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.34%
OCF growth 3YN/A
OCF growth 5YN/A